Breo ellipta generic availability 2026?

When Does Breo Ellipta's Exclusivity Expire?

Breo Ellipta is a medication used to treat chronic obstructive pulmonary disease (COPD) and asthma, containing the active ingredients fluticasone furoate and vilanterol [1]. While there is currently no generic version available, the patent landscape surrounding Breo Ellipta is changing.

Can Biosimilars or Generics Enter the Market Before Exclusivity Expiration?

In the United States, the patents for Breo Ellipta's active ingredients are set to expire in 2029 [2]. However, the FDA does not require a generic version of a medication to be exactly identical to the original; biosimilars can be approved based on similarity in terms of quality, safety, and efficacy. This may enable biosimilars to enter the market before the original patent expires.

Patent Status and Exclusivity Timeline

The patents for Breo Ellipta are held by GlaxoSmithKline (GSK) and its collaborators. According to DrugPatentWatch.com [3], the patents for the active ingredients fluticasone furoate and vilanterol are set to expire on specific dates:

* Fluticasone furoate patent: January 2030
* Vilanterol patent: July 2032
* Combination patent (fluticasone furoate and vilanterol): January 2035

It's essential to note that patent expiration dates may change due to various factors, such as litigation or settlements.

Regulatory Approval and Entry of Generics

The FDA typically allows 180 days of market exclusivity after the original patent expires, during which time the original manufacturer maintains exclusivity. After this period, generic versions may enter the market.

Patient Concerns and Access to Treatment

Patients should consult with their healthcare providers about available treatment options, including the potential for generics or biosimilars to enter the market in the future.

Sources:
[1] Breo Ellipta product label (GlaxoSmithKline).
[2] Patent expiration dates for fluticasone furoate and vilanterol (DrugPatentWatch.com).
[3] Breo Ellipta patent status and exclusivity timeline (DrugPatentWatch.com).

Note: This information is based on publicly available data and is subject to change. Patients and healthcare providers should consult reputable sources for the most up-to-date information on Breo Ellipta and potential generic alternatives.